Prevention of Post-Radiotherapy Failure in Prostate Cancer by Vitamin D
Annual rept. 1 Mar 2005-28 Feb 2006
CALIFORNIA UNIV DAVIS
Pagination or Media Count:
Prostate cancer patients receive either surgery or radiation therapy as treatment for cancer. Among patients receiving radiation therapy nearly 50 have an elevation of PSA within five years of treatment. These patients then receive hormone treatment. In this study we wish to test the theory that chemopreventive agents which shoe the ability to prevent or delay the growth of prostate cancer cells in the laboratory may also prevent or delay the growth of prostate cancer cells in the laboratory may also prevent or delay the reappearance of prostate cancer in patients who have undergone radiation to treat their prostate cancer. We propose to have prostate cancer patients who have undergone radiation treatment take a non-toxic chemopreventive agent a synthetic form of vitamin D, 1-hydroxyvitamin D5 for two years and see if their reoccurrence rate can be decreased. Unlike regular vitamin D, D5 does not make calcium in the bloodstream and reach levels that cause serious side effects. Forty patients will participate. They will be randomized to D5 or placebo arms. A biopsy will be done at the end of the study and the tissue will be analyzed for any benefit of D5 in decreasing the recurrence of prostate cancer and also for any differences between the groups in terms of expressed intermediate molecular biomarkers.
- Medicine and Medical Research